Search

Pegzilarginase

FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

Eltrombopag

ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked

Baxdrostat

On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].

Tolcapone

Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.

Methyclothiazide

A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

Anisindione

II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. … Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors

Mirdametinib

[L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

Ginkgo biloba

[L32789] _Ginkgo biloba_ is an herbal plant that is now cultivated worldwide. It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries. … _Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA

Phenyl trimethicone

Dichromate